Scale -


  • Revenue is 16927 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 20 %
  • Quarterly Revenue is 4292 Rs Cr; in Top Quartile
  • Quarterly Ebitda is 847 Rs Cr; in Top Quartile
  • Ebitda is 3798 Rs Cr; 5 Year CAGR is 15 %
  • PBT is 128 Rs Cr; Annual Decline is -76 %; in Bottom Quartile; 5 Year CAGR is -22 %
  • PAT is 369 Rs Cr; Annual Decline is -74 %; in Bottom Quartile; 5 Year CAGR is -22 %

Profitability -


  • PBDIT Margin is 22.43 %; Annual Decline is -22 %
  • PAT Margin is 2.17 %; Annual Decline is -77 %; in Bottom Quartile; 5 Year CAGR is -35 %
  • Quarterly Profit margin is 3 %; in Bottom Quartile

Return -


  • Asset Turnover is 28 %; 5 Year CAGR is 21 %; in Bottom Quartile
  • ROCE is 3.71 %; Annual Decline is -39 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -18 %
  • ROA is 0.6 %; Annual Decline is -65 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -34 %
  • ROE is 1.13 %; Annual Decline is -76 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -38 %

Efficiency -


  • Current Ratio is 1.22; Continuous Growth over 3 years; in Bottom Quartile
  • Inventory Turnover Ratio is 3.07; 5 Year CAGR is 42 %; in Bottom Quartile
  • Operating cash flow is 1994 Rs Cr; Annual Decline is -51 %
  • Quick Ratio is 0.79; in Bottom Quartile

Solvancy -


  • Debt/Equity is 0.44; Annual Decline is -46 %; in Top Quartile
  • Long term Debt is 10746 Rs Cr; Continuous Decline over 3 years; in Top Quartile; 5 Year CAGR is 28 %
  • Contingent Liabilities is 1962 Rs Cr; Continuous Decline over 3 years; in Top Quartile
  • Total Debt is 14825 Rs Cr; in Top Quartile; 5 Year CAGR is 32 %

Quality -


  • Operating cashflow/PAT is 5.41 %; Annual Growth is 90 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 46 %
  • Exceptional Items/PBT is -90 %; Annual Decline is -1859 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is -6 %; Annual Decline is -389 %; in Bottom Quartile
  • Operating cashflow/ebitda is 53 %; Annual Decline is -43 %
  • Current Tax/PAT is 120 %; Annual Growth is 366 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 52 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Biocon Limited Expands Global Access to Affordable Medicines Through Biosimilars and Generics
Biocon ranks No. 13 in Science magazine's 2026 biopharma employer list
stock insights biocon share recovery syngene q2 results impact
Biocon Share Price Rises 2.97% Today: Price and Fundamentals
Biocon Secures Yesintek Market Entry Rights in Nine Additional Countries
Biocon expands global reach of Stelara biosimilar to nine more markets
Biocon gets additional global market entry for Yesintek to treat autoimmune diseases
Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets
Biocon Touches Rs 325.50 on Yesintek Entry in Nine Markets
Biocon: 'Yesintek' ???????????? ????? ?????????
Buy, Sell Or Hold: Kalyan Jewellers, Biocon, Paytm, Reliance Industries, ITC And IDFC First Bank — Ask Profit
News by CNBC TV18 on TradingView, 2026-10-26 — cnbctv:2b4fe5561094b:0
Biocon Succession Plan: Kiran Mazumdar-Shaw Names Claire Mazumdar As Future Leader
Bonus + Stock Splits + Dividends + Buybacks From June 29-July 3: Bajaj, M&M, Biocon, TechM; 46 Stocks In Focus
Natural Biocon (India) Ltd. Estimates – BSE:NATURAL
Biocon Q1 Review: Expect Growth In Second Half Of 2022, Says CEO Siddharth Mittal
Biocon Shares Fall After July-September Earnings
Biocon Claims Earliest Pertuzumab Launch Dates With Perjeta Settlement
Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo
Biocon Secures Pebrilzo Launch Dates; Shares Fall 0.94%
Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates
Biocon settles patent dispute with Genentech over breast cancer drug
Biocon Settles Patent Dispute With Genentech; Shares Down
Biocon receives GST demand notice of over Rs 3.2 cr
Biocon Electric Files DRHP for IPO of Up to 59 Lakh Equity Shares
Upcoming IPO: Electrical products maker Biocon Electric files DRHP with SEBI